Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
EuroAPI gains on market debut after spin-off from Sanofi
06:56am, Friday, 06'th May 2022
Shares in EuroAPI, the drug ingredients business spun off from Sanofi, rose on their Paris stock market debut on Friday, defying a wider market decline.
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
03:54pm, Wednesday, 04'th May 2022 Zacks Investment Research
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Why Kymera Therapeutics Stock Is Getting Hammered Today
05:09pm, Tuesday, 03'rd May 2022 The Motley Fool
The biotech upset investors today with disappointing news for its lead program.
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
04:21pm, Monday, 02'nd May 2022 Zacks Investment Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
Sanofi (SNY) Q1 2022 Earnings Call Transcript
08:30pm, Friday, 29'th Apr 2022 The Motley Fool
SNY earnings call for the period ending March 31, 2022.
Seagen's (SGEN) Q1 Earnings & Revenues Surpass Estimates
04:43pm, Friday, 29'th Apr 2022 Zacks Investment Research
Seagen (SGEN) reports narrower-than-expected loss in the first quarter of 2022 while its revenues beat estimates.
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
06:35pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
02:52pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.
Sanofi SA (SNY) CEO Paul Hudson on Q1 2022 Results - Earnings Call Transcript
02:10pm, Thursday, 28'th Apr 2022
Sanofi SA (NASDAQ:SNY ) Q1 2022 Earnings Conference Call April 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO & Director John Reed - EVP & Global Head, Resea
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
12:52pm, Thursday, 28'th Apr 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Seeks FDA Emergency Use Nod For COVID-19 Shot In Kids 2-6
Moderna Inc (NASDAQ: MRNA) submitt
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
12:02pm, Thursday, 28'th Apr 2022
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines.
Sanofi posts higher earnings and sales, sees further growth ahead
01:46am, Thursday, 28'th Apr 2022
Sanofi SA on Thursday posted higher earnings and sales for the first quarter, driven by best-selling drug Dupixent and consumer healthcare, and said that it expects further growth in business earnings
Sanofi operating income up 16% on bestseller drug Dupixent
01:38am, Thursday, 28'th Apr 2022
French healthcare group Sanofi's first quarter adjusted earnings gained 16.2% on continued sales growth of its bestselling drug Dupixent.
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
06:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
04:00pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
